Cabaletta Bio
Biotechnology Research • 
Philadelphia, Pennsylvania, United States • 101-200 Employees
Company overview
| Headquarters | 2929 Arch St, Suite 600, Philadelphia, Pennsylvania 19104, US |
| Phone number | +12677593100 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotech, Rheumatology, Cell Therapy, Immunology, Autoimmune |
| Founded | 2017 |
| Employees | 101-200 |
| Socials |
Key Contacts at Cabaletta Bio
Huailiang Ma
Associate Director, Analytical Development
Jeff Hines
Associate Director, Talent Acquisition
Aditya Dandekar
Associate Director
Yan Li
Senior Director, Process Development
Christie Murphy
Director Of Supplier Management
Steven Nichtberger
Co-Founder, Chairman, & Ceo
Thomas Furmanak
Associate Director, Translational Medicine
Eric Jonas
Director, Data Management
Aaron Thomas Pharmd
Director, Clinical Trial Liaison
Rebecca Dryer-Minnerly
Director, Regulatory Scientist
Cabaletta Bio Email Formats
Cabaletta Bio uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@cabalettabio.com), used 73.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@cabalettabio.com | 73.9% |
{first name} | john@cabalettabio.com | 21.7% |
{first initial}.{second initial}{last name} | j.odoe@cabalettabio.com | 4.3% |
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Cabaletta Bio revenue & valuation
| Annual revenue | $12,500,000 |
| Revenue per employee | $72,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $40,000,000 |
| Total funding | $187,000,000 |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Cabaletta Bio has 88 employees across 13 departments.
Departments
Number of employees
Funding Data
Explore Cabaletta Bio's funding history, including investment rounds, total capital raised, and key backers.
Cabaletta Bio Tech Stack
Discover the technologies and tools that power Cabaletta Bio's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Web servers
Security
JavaScript libraries
Tag managers
Hosting
JavaScript libraries
JavaScript libraries
Miscellaneous
Miscellaneous
Analytics
Pakistan
Spain
Frequently asked questions
4.8
40,000 users
